NBRV - Nabriva -9.4% on FDA review date for Contepo April, 30 2019 06:03 PM Nabriva Therapeutics plc Nabriva Therapeutics (NASDAQ:NBRV) is off 9.4% after hours on the arrival of its priority review for Contepo (fosfomycin).More news on: Nabriva Therapeutics plc, Healthcare stocks news, Stocks on the move Read more ...